Literature DB >> 20979456

Staphylococcal superantigens cause lethal pulmonary disease in rabbits.

Kristi L Strandberg1, Jessica H Rotschafer, Sara M Vetter, Rebecca A Buonpane, David M Kranz, Patrick M Schlievert.   

Abstract

BACKGROUND: The Centers for Disease Control and Prevention (CDC) and others reported that methicillin-resistant S. aureus (MRSA) are significant causes of serious human infections, including pulmonary illnesses. We investigated the role played by superantigens in lung-associated lethal illness in rabbits.
METHODS: A rabbit model was established to investigate the potential role played by superantigens, staphylococcal enterotoxin B (SEB), staphylococcal enterotoxin C (SEC), and toxic shock syndrome toxin-1 (TSST-1). Rabbits received intrabronchial community-associated (CA) MRSA strains USA200 (TSST-1(+)), MW2 (SEC(+)), c99-529 (SEB(+)), or purified superantigens. Some rabbits were preimmunized against superantigens or treated with soluble high-affinity T cell receptors (Vβ-TCR) to neutralize SEB and then challenged intrabronchially with CA-MRSA or superantigens.
RESULTS: Rabbits challenged with CA-MRSA or superantigens developed fatal, pulmonary illnesses. Animals preimmunized against purified superantigens, or treated passively with Vβ-TCRs and then challenged with CA-MRSA or superantigens, survived. Lung histological analysis indicated that nonimmune animals developed lesions consistent with necrotizing pneumonia after challenge with CA-MRSA or purified superantigens. Superantigen-immune animals or animals treated with soluble Vβ-TCRs did not develop pulmonary lesions.
CONCLUSIONS: Superantigens contribute to lethal pulmonary illnesses due to CA-MRSA; preexisting immunity to superantigens prevents lethality. Administration of high-affinity Vβ-TCR with specificity for SEB to nonimmune animals protects from lethal pulmonary illness resulting from SEB(+) CA-MRSA and SEB.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20979456      PMCID: PMC2974057          DOI: 10.1086/657156

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  36 in total

Review 1.  Exotoxins of Staphylococcus aureus.

Authors:  M M Dinges; P M Orwin; P M Schlievert
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

Review 2.  Toxic shock syndrome and bacterial superantigens: an update.

Authors:  J K McCormick; J M Yarwood; P M Schlievert
Journal:  Annu Rev Microbiol       Date:  2001       Impact factor: 15.500

3.  Crystal structure of a complete ternary complex of TCR, superantigen and peptide-MHC.

Authors:  Limin Wang; Yiwei Zhao; Zhong Li; Yi Guo; Lindsay L Jones; David M Kranz; Walid Mourad; Hongmin Li
Journal:  Nat Struct Mol Biol       Date:  2007-01-14       Impact factor: 15.369

4.  Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia.

Authors:  Juliane Bubeck Wardenburg; Taeok Bae; Michael Otto; Frank R Deleo; Olaf Schneewind
Journal:  Nat Med       Date:  2007-12       Impact factor: 53.440

5.  Comparative analysis of lipopolysaccharide-induced tumor necrosis factor alpha activity in serum and lethality in mice and rabbits pretreated with the staphylococcal superantigen toxic shock syndrome toxin 1.

Authors:  M M Dinges; P M Schlievert
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

Review 6.  Use of intravenous immunoglobulin in the treatment of staphylococcal and streptococcal toxic shock syndromes and related illnesses.

Authors:  P M Schlievert
Journal:  J Allergy Clin Immunol       Date:  2001-10       Impact factor: 10.793

7.  Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia.

Authors:  Maria Labandeira-Rey; Florence Couzon; Sandrine Boisset; Eric L Brown; Michele Bes; Yvonne Benito; Elena M Barbu; Vanessa Vazquez; Magnus Höök; Jerome Etienne; François Vandenesch; M Gabriela Bowden
Journal:  Science       Date:  2007-01-18       Impact factor: 47.728

8.  Alpha and beta chains of hemoglobin inhibit production of Staphylococcus aureus exotoxins.

Authors:  Patrick M Schlievert; Laura C Case; Kimberly A Nemeth; Catherine C Davis; Yiping Sun; Wendy Qin; Fancheng Wang; Amanda J Brosnahan; John A Mleziva; Marnie L Peterson; Bruce E Jones
Journal:  Biochemistry       Date:  2007-11-20       Impact factor: 3.162

9.  Invasive methicillin-resistant Staphylococcus aureus infections in the United States.

Authors:  R Monina Klevens; Melissa A Morrison; Joelle Nadle; Susan Petit; Ken Gershman; Susan Ray; Lee H Harrison; Ruth Lynfield; Ghinwa Dumyati; John M Townes; Allen S Craig; Elizabeth R Zell; Gregory E Fosheim; Linda K McDougal; Roberta B Carey; Scott K Fridkin
Journal:  JAMA       Date:  2007-10-17       Impact factor: 56.272

Review 10.  Secreted virulence factor comparison between methicillin-resistant and methicillin-sensitive Staphylococcus aureus, and its relevance to atopic dermatitis.

Authors:  Patrick M Schlievert; Kristi L Strandberg; Ying-Chi Lin; Marnie L Peterson; Donald Y M Leung
Journal:  J Allergy Clin Immunol       Date:  2010-01       Impact factor: 10.793

View more
  40 in total

Review 1.  The potential use of toxin antibodies as a strategy for controlling acute Staphylococcus aureus infections.

Authors:  Gordon Y C Cheung; Michael Otto
Journal:  Expert Opin Ther Targets       Date:  2012-04-25       Impact factor: 6.902

2.  Role of miRNA in the regulation of inflammatory genes in staphylococcal enterotoxin B-induced acute inflammatory lung injury and mortality.

Authors:  Roshni Rao; Prakash Nagarkatti; Mitzi Nagarkatti
Journal:  Toxicol Sci       Date:  2015-01-05       Impact factor: 4.849

3.  Vaccination against Staphylococcus aureus pneumonia.

Authors:  Adam R Spaulding; Wilmara Salgado-Pabón; Joseph A Merriman; Christopher S Stach; Yinduo Ji; Aaron N Gillman; Marnie L Peterson; Patrick M Schlievert
Journal:  J Infect Dis       Date:  2013-12-19       Impact factor: 5.226

4.  Bacterial Toxins-Staphylococcal Enterotoxin B.

Authors:  Bettina C Fries; Avanish K Varshney
Journal:  Microbiol Spectr       Date:  2013-12

5.  Engineering a soluble high-affinity receptor domain that neutralizes staphylococcal enterotoxin C in rabbit models of disease.

Authors:  D M Mattis; A R Spaulding; O N Chuang-Smith; E J Sundberg; P M Schlievert; D M Kranz
Journal:  Protein Eng Des Sel       Date:  2012-11-15       Impact factor: 1.650

6.  Therapeutic blockade of CD54 attenuates pulmonary barrier damage in T cell-induced acute lung injury.

Authors:  Julia Svedova; Antoine Ménoret; Payal Mittal; Joseph M Ryan; James A Buturla; Anthony T Vella
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-05-04       Impact factor: 5.464

7.  CD1d-independent activation of invariant natural killer T cells by staphylococcal enterotoxin B through major histocompatibility complex class II/T cell receptor interaction results in acute lung injury.

Authors:  Sadiye Amcaoglu Rieder; Prakash Nagarkatti; Mitzi Nagarkatti
Journal:  Infect Immun       Date:  2011-05-31       Impact factor: 3.441

Review 8.  Recurrent infections and immune evasion strategies of Staphylococcus aureus.

Authors:  Hwan Keun Kim; Vilasack Thammavongsa; Olaf Schneewind; Dominique Missiakas
Journal:  Curr Opin Microbiol       Date:  2011-11-14       Impact factor: 7.934

9.  Humanized staphylococcal enterotoxin B (SEB)-specific monoclonal antibodies protect from SEB intoxication and Staphylococcus aureus infections alone or as adjunctive therapy with vancomycin.

Authors:  Avanish K Varshney; Xiaobo Wang; Jennifer MacIntyre; Richard S Zollner; Kerry Kelleher; Oleg V Kovalenko; Ximo Pechuan; Fergus R Byrne; Bettina C Fries
Journal:  J Infect Dis       Date:  2014-05-05       Impact factor: 5.226

Review 10.  Models matter: the search for an effective Staphylococcus aureus vaccine.

Authors:  Wilmara Salgado-Pabón; Patrick M Schlievert
Journal:  Nat Rev Microbiol       Date:  2014-07-07       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.